Multiple Sclerosis, Primary Progressive
Information
- Disease name
- Multiple Sclerosis, Primary Progressive
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04544449 | Active, not recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | October 26, 2020 | December 18, 2026 |
| NCT01433497 | Completed | Phase 3 | Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis | August 2011 | February 2020 |
| NCT01917019 | Completed | Phase 3 | A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis | August 2013 | March 2017 |
| NCT01982942 | Completed | Phase 2 | Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis | November 2013 | December 2017 |
| NCT02305264 | Completed | N/A | Imaging of Intracerebral Inflammation in MS | March 19, 2012 | September 10, 2018 |
| NCT02506751 | Completed | Phase 1 | Open-label Study of Liothyronine in MS | July 2015 | September 18, 2017 |
| NCT02688985 | Completed | Phase 3 | Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) | April 29, 2016 | April 11, 2023 |
| NCT02913157 | Completed | Phase 2 | Hydroxychloroquine in Primary Progressive Multiple Sclerosis | November 2016 | June 2021 |
| NCT02988401 | Completed | Phase 1/Phase 2 | Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis | December 1, 2017 | December 17, 2021 |
| NCT03424538 | Completed | N/A | The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients | February 5, 2018 | June 10, 2018 |
| NCT03679468 | Completed | N/A | Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation | March 18, 2019 | February 3, 2023 |
| NCT06436131 | Completed | N/A | The Effects of In-phase Bilateral Exercise in People With Progressive Multiple Sclerosis | October 2, 2023 | December 22, 2023 |
| NCT04545372 | Completed | N/A | Aerobic Exercises for Multiple Sclerosis | February 2, 2015 | August 6, 2020 |
| NCT04550650 | Completed | N/A | Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients | April 6, 2018 | September 1, 2020 |
| NCT05663853 | Completed | An Observational Biomarker Study in Multiple Sclerosis (MS) Patients | March 28, 2023 | April 30, 2024 | |
| NCT01194570 | Completed | Phase 3 | A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | March 2, 2011 | December 31, 2022 |
| NCT06384976 | Not yet recruiting | Phase 2 | A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | April 2024 | January 2029 |
| NCT05385731 | Not yet recruiting | N/A | MUSCLE - Nordic Walking in MUltiple SCLErosis | August 2, 2022 | December 30, 2024 |
| NCT05204459 | Recruiting | MS-ResearchBiomarkerS | November 11, 2021 | November 11, 2041 | |
| NCT05359653 | Recruiting | Phase 1/Phase 2 | Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy | August 1, 2023 | June 1, 2025 |
| NCT05496881 | Recruiting | N/A | Exercise Effects in Multiple Sclerosis | June 15, 2022 | April 30, 2025 |
| NCT04035005 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | August 12, 2019 | November 11, 2030 |
| NCT03455582 | Recruiting | N/A | Cognition Evolution and MRI Markers in PPMS Patients on 2 Years | September 24, 2018 | March 2026 |
| NCT04918225 | Recruiting | Motor Asymmetry in Progressive Multiple Sclerosis Patients | November 3, 2021 | May 2026 | |
| NCT06138132 | Recruiting | Phase 1 | A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis | April 10, 2024 | June 2027 |
| NCT05122559 | Recruiting | Phase 2 | Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis | February 16, 2022 | February 2026 |